Poster Session

Abstract/

Poster #

Name

Title

29

Maria Al Haddad

Characterization of an Activating Cancer-Associated PI3KÉ‘ RBD Mutant

87

Amber Amparo

Defining the role of mitochondrial dynamics in regulating PDAC cell sensitivity to ERK and KRAS inhibition

79

Fikret Aydin

Understanding the Relation between Membrane Orientational States of RAS-RAF and Lipid-protein Fingerprints using Deep Learning

63

Saskia Brachmann

Mechanisms Of Tumor Resistance To KRASG12C/SHP2 Co-Inhibition In Non-Small Cell Lung Cancer Models

11

Kate Brown

RAS-Precision Medicine (RAS-PM) Trans-Atlantic Partnership: RAS and NF1 Co-Mutation in Non-Small Cell Lung Cancer (NSCLC)

9

Leiah Carey

Combinatory Structural Biology of NRAS Q61 Melanomagenic Mutants

81

Beatriz Carreno

KRAS-specific T Cell Receptors Directed at Common G12 Variants Exhibit Potent Cytolytic Activity and CD8 Co-Receptor Independence

99

Christophe Cataisson

RAS Oncogene Signal Strength Regulates Matrisomal Gene Expression and Tumorigenicity of Mouse Keratinocytes

57

Wen-Hsuan Chang

Investigating the Effects of the KRAS G12D inhibitor, MRTX1133, in Pancreatic Cancer Cells

65

Jonathan Chernoff

Unique Metabolic Effects of KRAS G12V in Colorectal Cancer Cells

39

Geoff Clark

A novel pan-RAS inhibitor for Malignant Peripheral Nerve Sheath Tumors

25

Robert D'Ippolito

A Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement

27

Kristina Drizyte-Miller

Targeting Mitochondrial Activity Using Small Molecule Activators of Mitochondrial Protease ClpP for Pancreatic Cancer Treatment

69

Claire Gates

Evaluating the Efficacy of Combined ERK and Autophagy Inhibition in RAS-Mutant Cancers

37

Jill Hallin

Effects of Adagrasib on Oncogenic Signaling, Immune Cell Regulation and Biomarkers of Response in Preclinical and Preliminary Clinical Analyses

55

Moon Hee Yang

Allosteric Regulation of Switch-II Controls K-Ras Oncogenicity

31

Chuan-Hsiang Huang

Cell autonomous and non-autonomous effects of oncogenic Ras mutations revealed by highly multiplexed biosensor barcoding

1

Anisha Jain

Evaluation of Repurposed Drugs Targeting SHP2 in Combination with Upstream Activators of KRAS to Conquer Resistance in KRAS Mutant Cells of NSCLC

107

Prakrit Jena

Phospholipase A2 Lipid Remodeling Activity Regulates Toxic Lipid Peroxide Accumulation in Cancer to Protect from Cell Death

43

Christian Johnson

Ala59 Mutants of KRAS Cooperate with Other MAPK Signaling Pathway Mutations in the Colon

61

Hyungdong Kim

Translation Initiation Factor 2B (eIF2B) stimulates mutant KRAS function in cancer

109

Robert L Kortum

51

Ozgun Le Roux

A Tissue Sensitivity Atlas To Oncogenic RAS Mutations

45

Chendi Li

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant non-small cell lung cancers to combined KRAS G12C + MCL-1 blockade

3

Colin Lindsay

RAS-BIO: A Comprehensive RAS Cancer Biobank Within the UK National Health Service

95

Andrew Lu

Targeting cancer cells with synthetic protein circuits

77

Anna Magdalena Koester

Multiplexed Super Resolution Microscopy for the Investigation of Nanoscale Spatial Systems Biology of Ras small GTPases on the Membrane

15

Christophe Marcireau

Identification of KRAS suppressor genes: An ORFeome library screening

5

Chris Marshall

NMR Studies of the Dimerization of Wild-Type and Mutant KRAS4b on a Lipid Bilayer

101

William Marsiglia

A Toolkit To Measure The Effects Of Protein-Protein Interactions On MAPK And PI3K-AKT Inhibitor Pharmacology

35

Van Ngo

Dynamics of Full CRaf Kinase in Unphosphorylated State

49

John O'Bryan

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of oncogenic RAS mutants

21

Jonathan Pachter

The RAF/MEK Clamp VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers: Beyond Ovarian and Lung Cancers

33

Bianca Parisi

PDE6D Dependent Trafficking of K-Ras to Stemness Promoting Centriolar Organelles

91

Unnatiben Patel

Selective Targeting Of NRAS (Q61R) Mutant With Monobodies

71

Olesja Popow

Dissecting The Tissue-Specific Oncogenic Activity Of K-RasG12D

103

Abhineet Ram

A Data-Driven Approach to Predicting Ras/MAPK Pathway Activation with Downstream Target Genes.

85

Ben Ringham-Terry

The Role of SHOC2 in Skin Inflammation

23

Ryan Robb

Interplay and Compensation Between Autophagy and Macropinocytosis in ERK MAPK Inhibited Pancreatic Cancer

73

Karla Satchell

The RRSP Ras Protease Cleaves Ras to Drive Tumor Regression in Patient-derived Pancreatic Cancer Xenografts

17

Genevieve Seabrook

Real-Time NMR Multiplexed GEF Assay Allowing the Monitoring of Multiple GTPases Nucleotide Exchange from Cells and Organoids, Simultaneously.

105

Nancy Sealover

WT RAS Signaling is an Essential Therapeutic Target in RAS-Mutated Cancers

97

Russell Spencer-Smith

Germline RASopathy Mutations Provide Insights Into The Regulation Of Raf Family Kinases

53

Beth Stronach

Advocating for Research on RASopathies: Genetic Disorders of the RAS Signaling Pathway

13

Kumiko Ui-Tei

SNPD-siRNA: an siRNA Specifically Suppresses the Expression of a Target Gene with Single Nucleotide Mutation

47

Wei Wei

Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition

67

Yong Zhou

Remodeling PS Acyl Chain Profile Regulates the Nanoclustering and Oncogenesis of KRAS4B

Abstract/

Poster #

Name

Title

10

Yoshimasa Asano

Development of siRNA for KRAS and BRAF mutations using a cancer cell-derived Xenograft

84

Philip Bryan

Engineering subtilisin proteases that specifically degrade active RAS

102

Rachel Burge

KRAS allele-specific interactions reveal potential mechanisms in pancreatic cancer tumor initiation

96

Tim Carpenter

Dynamics And Lipid Interactions Of The RAS-RBD-CRD Protein Complex

50

Fa-An Chao

Probing ‘invisible’ conformational dynamics in KRAS using methyl adiabatic relaxation dispersion.

70

Arthur Chow

An Antagonist of KSR1-Driven Adaptive Resistance to Clinical RAS-MAPK Inhibitors

40

Geoff Clark

A Novel RAS Inhibitor for Pancreatic Cancer

56

Jonathan DeLiberty

Dual MEK and PIKfyve Inhibition as an Efficacious Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma

6

Matthias Drosten

Capicua Is A Barrier To Lung Cancer Development Driven By KRAS Oncogenes

32

Alexander (Cole) Edwards

TEAD Inhibition Overcomes YAP1/TAZ-driven Resistance To RAS Inhibitors In KRASG12C-Mutant Cancers

38

Natalia Garcia

Preclinical Efficacy of the CRAF and BRAF Inhibitor LXH254 in combination with the MEK Inhibitor Trametinib in RAS-mutant and NF1-altered Rhabdomyosarcoma

42

Xiangyu Ge

Wild-type RAS/MAPK Signaling Complexes Mediate Adaptive Resistance to KRAS Inhibition in PDAC.

106

Bill Gillette

Frederick National Laboratory Protein Production At The RAS Initiative

30

Jacob Haling

SOS1 Inhibition Augments the Anti-Tumor Response of Targeted KRAS/MAPK Inhibitors

14

Nicholas Heimann

How to Design Effective Combination Therapies with KRAS Inhibitors

64

Frank Heinrich

The Structure Of Membrane-Bound KRas From Neutron Reflectometry And Molecular Simulation.

16

Priya Hibshman

MYC is a Major Driver of KRAS-Dependent Metabolic Abnormalities in Pancreatic Cancer

98

Aaron Hobbs

NUTRIENT AVAILABILITY REGULATES MACROPINOCYTOSIS AND SMALL MOLECULE INHIBITOR RESISTANCE IN KRASG12R-MUTANT PANCREATIC DUCTAL ADENOCARCINOMA

108

Matthew Holderfield

RM-042, a RAS(MULTI) (ON) Inhibitor Reveals that KRAS G12X Mutant Cancer Cells Are Highly RAS-Addicted

90

Joshua Homer

High Throughout Accelerated SuFEx Click Chemistry: A Tool For Discovering Lead Candidates Against Ras-Dependent Cancers

4

Christopher Kemp

Pharmacological Targeting of TFIIH Suppresses KRAS Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

68

Jeffrey Klomp

Defining the KRAS-Regulated Transcriptome in KRAS-Mutant Pancreatic Cancer

36

Yoshiaki Kobayashi

The siRNA Seed Region Is Composed of Two Functionally Different Domains Which Have Different Effects on RNA Interference and Off-target Activities in Response to 2´-OMe Modifications

58

Kari Kopra

Protein-Probe – A Versatile Platform for Label-Free RAS Stability and Interaction Characterization

62

Antonis Koromilas

The integrated stress response (ISR) is a focal point of oncogenic pathways in the development of mutant KRAS lung cancer

88

Jason Kwon

Comprehensive structure-function evaluation of the SHOC2 holophosphatase reveals disease mechanisms and therapeutic opportunities

24

Ye Lee

Targeting Valosin-Containing Protein (VCP), a Regulator of the DNA Damage Response, for Pancreatic Cancer Treatment

18

Rachel Lew

Enhanced BRAF Engagement By NRAS Mutants Capable Of Promoting Melanoma Initiation

66

Yonglan Liu

The Mechanism of Bcr-Abl Activation in Chronic Myelogenous Leukemia

80

Barbara Mair

The Other SOS: Characterization of SOS2 as a Potential Drug Target in KRASmut Cancers

26

Ana Martin-Vega

Mechanisms Of ERK Action In MEK Inhibitor-Insensitive Lung Cancers

60

Lauren McGee

YAP signaling promotes resistance to MEK and AKT inhibition in NF1-related MPNSTs

82

Yan Ming Ching

Dual Inhibition of AXL and ERK Overcomes Compensatory Feedback Mechanisms Mediated by Adaptive Responses in PDAC

74

Mubashir Mintoo

RAS Inhibition Limits Neuroblastoma Tumorigenesis and Promotes Retinoic Acid Induced Differentiation in a Subset of NBL Tumors

72

Bjoern Papke

Deciphering Cell Cycle Plasticity to ERK Inhibition in KRAS-driven Pancreatic Cancer Cells at the Single-cell Level

92

Unnatiben Patel

Selective Targeting Of NRAS (Q61R) Mutant With Monobodies

44

Ajit Prakash

Characterization Of Kinetic And Redox Properties Of Oncogenic KRAS-G12C Inhibitors

100

Yanixa Quinones Aviles

Differential pathway engagement and the biological consequences of KRAS variants in cancer

110

Kent Rossman

A Crystallographic View of the Fast-Cycling KRAS Mutant, K117N

8

Elisabeth Schaffner-Reckinger

Novel High Affinity Inhibitors Of The K-Ras Trafficking Chaperone PDE6D

48

shweta shree

Nanodisc Based System For Investigating KRas4b Trafficking.

86

Kamini Singh

KRAS (G12C) mediated regulation of mRNA translation program

34

Hitendra Solanki

Cell Cycle and the DNA Damage Response Signaling as New Vulnerabilities in Cells with Acquired Resistance to Sotorasib

20

Clint Stalnecker

Determination of KRAS- and ERK-regulated Phosphoproteomes in KRAS-mutant Cancers

52

Yaakov Stern

CDK12/13 Inhibition Antagonizes Resistance to KRASG12C Inhibitors

46

Heidi Vieira

KSR1-Dependent Tumor Initiation in Ras-Driven Cancers

76

Johanna Virta

A Systematic Approach to Discovery of Protein-Protein Interaction Stabilizers

78

Elizabeth  Vo

Discovery and Characterization of Oncogenic KRAS:RAF1 Conformational Modulators With a Novel Mechanism of Action in RAF1-Dependent Cancer Cells

104

Andrew Waters

Identification of Resistance Mechanisms to Direct KRAS Inhibition in Pancreatic Cancer